Active Ingredient History
Juno Therapeutics Inc was an American biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs. The company raised $300 million through private funding and a further $265 million through their IPO. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Lymphoma, Follicular (approved 2021)
Lymphoma, Large B-Cell, Diffuse (approved 2021)
Immune System Diseases (Phase 2)
Immunoproliferative Disorders (Phase 2)
Leukemia, B-Cell (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Lymphatic Diseases (Phase 2)
Lymphoma (Phase 2)
Lymphoma, B-Cell (Phase 2)
Lymphoma, Follicular (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Lymphoma, Large-Cell, Immunoblastic (Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Lymphoproliferative Disorders (Phase 2)
Neoplasms (Phase 2)
Neoplasms by Histologic Type (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
